Why the study?
The association between a history of cancer and clinical outcomes in patients with acute myocardial infarction remained unclear.
Does a history of cancer increase the risk of mortality and adverse clinical events in patients with acute myocardial infarction?
Does a history of cancer increase the risk of mortality and adverse clinical events in patients with acute myocardial infarction?
A history of cancer in patients with acute myocardial infarction is associated with significantly higher all-cause mortality, driven by non-cardiovascular and cancer deaths, particularly in patients under 75 years of age.
Cancer history was associated with higher AMI mortality; leaves open whether it should alter potent P2Y12 inhibitor strategies in practice.
Background The association between a history of cancer and clinical outcomes in patients with acute myocardial infarction (AMI) remains unclear. This study aimed to analyze the characteristics and clinical outcomes of AMI patients based on their history of cancer in a contemporary cohort undergoing antithrombotic therapy with potent P2Y 12 inhibitors. Methods Consecutive patients with spontaneous onset were enrolled in the Japan AMI Registry (JAMIR), a multi-center, nationwide prospective registry. The outcomes included all-cause death, major bleeding, and composite ischemic events defined as cardiovascular (CV) death, MI, and ischemic stroke. Results A total of 3,411 AMI patients were enrolled with a median follow-up duration of 358 days. Among those, 292 patients (8.6 %) had a history of cancer. They were older and had lower body mass index. While they had a similar risk of composite ischemic event and major bleeding, they were at higher risk for all-cause mortality than those without (adjHR 1.64 [95 %CI 1.16–2.32], P = 0.005). The risk for non-CV death and death due to cancer were higher in the cancer group (adjHR 2.05 [1.24–3.39], P = 0.005; adjHR 18.16 [6.76–48.97], P < 0.001, respectively). When further stratified by age, the difference in all-cause mortality became pronounced in the group aged < 75 years but not in the group aged ≥ 75 years (adjHR 3.32 [1.88–5.85] and 1.26 [0.81–1.96], respectively; P-interaction = 0.008). Conclusion The JAMIR demonstrated that a history of cancer was associated with increased mortality in AMI patients aged < 75 years. These results might suggest the need for a multidisciplinary approach to improve their prognosis.
No takes yet. Share an insight, caveat, or question.
Adachi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: